Go to contentGo to menuGo to searchGo to the news list

Micro et Nanomédecines Translationnelles

Main navigation



    Joël Eyer's Research Projet is supported through 'Plan Cancer Inserm'

    Joël Eyer's Research Projet is supported through 'Plan Cancer Inserm'

    • Share this page on social networks
    • E-mail this page

      Send by mail

      Separated by coma
    • Print this page

    Microrobots Targeting Glioblastoma

    Glioblastoma multiform (GBM) is the most frequent and aggressive cancer of the nervous system (5 cases/year for 100.000 habitants). The first line chemotherapy includes alkylating agent Temozolomide concomitantly with radiotherapy (Stupp protocol), but the average survival is limited to 15 months. Classical anti-cancer therapies show poor efficacy for GBM because of their low specificity and toxic effect on healthy cells.

    Team 1 identified a peptide (NFL peptide), which 1- enters specifically in all GBM tested (rat, mouse and human), 2- targets the entry of lipid nanocaspules into GBM cells, and 3- inhibits GBM cell division in vitro and in vivo on rats with a GBM tumor implanted in the brain (Bocquet et al. 2009, Berges et al. 2012, Balzeau et al. 2013).

    Team 2 (Laboratoire PRISME, INSA-CVL, Bourges) has developed superparamagnetic microrobots carriers guided in real time by  tri-axial Helmholtz coils systems. These microrobots are magnetically actuated and steered by a low-strength rotating magnetic field.

    Team 3 (Laboratoire GREMAN, INSA-CVL, Blois) has developed during the last 15 years processes in order to synthetize well-controlled porous silicon layers for various applications (microelectronics, energy or sensors). Recently, this group has shown that it is able to produce porous silicon micro particles of different sizes and able to carrier drugs and magnetic nanoparticles.

    We will synergize our expertise to functionalize microrobots with the NFL peptide in order to develop Microrobots Targeting Glioblastoma (MTG). These MTG filled with a fluorochrome will be tested in vitro for their capacity to target GBM versus healthy cells. Then, they will be injected intravenously in rats bearing a GBM tumor to evaluate their capacity to cross the blood-brain-barrier, to target the tumor, and to reduce its development when filled with cytotoxic products. Team 1 will bring its biological and biochemical expertise on GBM cancer research, and Team 2 and 3 will provide the physics, mathematics and engineering sciences to the development of therapeutic magnetic micro carriers guided by magnetic gradients provided by tri-axial Helmholtz coils system.

    This strategy provides a minimally invasive surgery together with an optimized concentration and delivery of therapeutic principle to the tumor, consequently lowering the toxic effects on healthy cells.


    contact : Joël Eyer (joel.eyer @ univ-angers.fr)